Moreover, increased complex formation of the ANKHD1/YAP complex has been identified in numerous cancer types due to downregulation of the Hippo signalling pathway, including non-small cell lung cancer [53], colorectal cancer [54], prostate cancer [51], and breast cancer [10]. Here, ANKHD1 is linked to prostate carcinoma.